OncoMatch/Clinical Trials/NCT04136886
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Is NCT04136886 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Cisplatin for nasopharyngeal carcinoma.
Treatment: Cisplatin — The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT3, RT4
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radiation therapy — first course
More than 1 year from the end of the first course of radiotherapy
Cannot have received: anti-tumor treatment
Prior anti-tumor treatment after diagnosis of local recurrence
Lab requirements
Blood counts
WBC count ≥4×10^9/L, neutrophile granulocyte count ≥1.5×10^9/L, PLT count ≥100×10^9/L, Hb ≥9g/L
Kidney function
creatinine ≤ 1.5 times of upper normal limits
Liver function
Total bilirubin, AST, ALT ≤ 2.0 times of upper normal limits
WBC count ≥4×10^9/L, neutrophile granulocyte count≥1.5×10^9/L, PLT count ≥100×10^9/L, Hb ≥9g/L; Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of upper normal limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04136886 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor treatment disqualifies patients from enrollment.
What disease stage is eligible?
Stage RT3 or RT4 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages